New Routes of Insulin for Diabetes Treatment
-
Published:2023-03-22
Issue:
Volume:
Page:228-241
-
ISSN:2581-9429
-
Container-title:International Journal of Advanced Research in Science, Communication and Technology
-
language:en
-
Short-container-title:IJARSCT
Author:
Mangesh Shalik Holgare 1, Nitin B. Kohale 1, Suraj B. Rathod 1
Affiliation:
1. Vardhman College of Pharmacy, Koli, Karanja (Lad), Washim, Maharashtra, India
Abstract
Diabetes is a chronic condition marked by insufficient insulin production and the subsequent hyperglycemia. Optimal diabetes control has an impact on both microvascular and macrovascular disease, which are both diabetic consequences. Subcutaneous insulin injections or continuous infusions are frequently used by people with diabetes to manage their blood sugar levels. Given that insulin injection therapy is difficult for many patients, novel routes of insulin administration are of interest in the diabetes sector. Inhalational insulin administration will be covered in this review. The effectiveness of inhaled insulin in comparison to subcutaneous insulin in the various populations with diabetes iscovered, as well as its safety. Additionally, the experience and challenges associated with the creation and promotion of insulin for inhalation are reviewed.
Publisher
Naksh Solutions
Reference74 articles.
1. Centers for Disease Control and Prevention. “National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011.” Atlanta, GA: US department of health and human services, centers for disease control and prevention 201, no. 1 (2011): 2568-2569. 2. Bakker, W., Eringa, E.C., Sipkema, P. and van Hinsbergh, V.W., 2009. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and tissue research, 335(1), pp.165-189. 3. Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D. and Multiple Risk Factor Intervention Trial Research Group, 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes care, 16(2), pp.434-444. 4. Krolewski, A.S., Kosinski, E.J., Warram, J.H., Leland, O.S., Busick, E.J., Asmal, A.C., Rand, L.I., Christlieb, A.R., Bradley, R.F. and Kahn, C.R., 1987. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. The American journal of cardiology, 59(8), pp.750-755. 5. Laing, S.P., Swerdlow, A.J., Slater, S.D., Burden, A.C., Morris, A., Waugh, N.R., Gatling, W., Bingley, P.J. and Patterson, C.C., 2003. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia, 46(6), pp.760-765.
|
|